Unknown

Dataset Information

0

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.

ABSTRACT:

SUBMITTER: Yi JH 

PROVIDER: S-EPMC7968880 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study∗
| S-EPMC12346063 | biostudies-literature
Unknown Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
| S-EPMC10830708 | biostudies-literature
Unknown A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma.
| S-EPMC10758639 | biostudies-literature
Unknown Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
| S-EPMC4513941 | biostudies-literature
Unknown Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
| S-EPMC10912842 | biostudies-literature
Unknown Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
| S-EPMC9678091 | biostudies-literature
Unknown Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.
| S-EPMC9631549 | biostudies-literature
Unknown Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.
| S-EPMC12597645 | biostudies-literature
Unknown Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
| S-EPMC8905688 | biostudies-literature
Unknown A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
| S-EPMC9631700 | biostudies-literature